RBC Biotech Targets Shift
RBC Capital Adjusts Biotech Stock Price Targets, Maintaining Outperform Ratings for Key Names.
Anonymous
Key Points
1
Target revisions implied by the five RBC notes show three price-target increases (United Therapeutics to about $70.4, Rhythm Pharmaceuticals to about $141, Mirum Pharmaceuticals to about $148) and two reductions (Nuvation Bio to about $19, Legend Biotech to about $63).
2
All three stocks with raised targets (United Therapeutics, Rhythm, Mirum) are described as maintained at an Outperform rating, signaling RBC’s continued bullish stance on these names even as targets move higher.
3
The two names with lower targets (Nuvation Bio and Legend Biotech) also carry an Outperform stance in these notes, indicating a tempered near-term upside despite the downgrade in targets.
4
The set of articles illustrates RBC's practice of applying a targeted, mixed-book approach (Outperform with price-target revisions) across diverse biotech names rather than a uniform sector-wide stance.
BioCryst Pharmaceuticals got a boost this week after RBC Capital raised its price target on the stock to $14 and kept its Outperform rating, according to TipRanks. The move signals growing confidence in BioCryst's commercial pipeline and near-term growth prospects.
The BioCryst upgrade is part of a wider sweep of biotech target revisions from RBC Capital. The bank updated price targets across at least eight biotech names, raising some and cutting others, while keeping most stocks at an Outperform rating, Benzinga reported.
RBC Lifts Targets for United, Rhythm, and Mirum
Three biotech stocks got higher price targets from RBC in the same round of notes. United Therapeutics saw its target raised to $704. Rhythm Pharmaceuticals climbed to $141. Mirum Pharmaceuticals reached $148. All three kept their Outperform ratings, according to Benzinga.
Outperform means RBC expects the stock to beat the broader market over the next 12 months. Raising targets while keeping that rating signals the bank sees even more upside ahead. For these three names, RBC appears to believe pipeline progress and near-term catalysts justify higher valuations.
Nuvation and Legend Face Trimmed Price Targets
Not every biotech got good news. RBC cut its price target on Nuvation Bio to $19 and trimmed its target on Legend Biotech to $63, Benzinga reported. Both stocks still kept their Outperform ratings, which is an unusual split.
Keeping an Outperform while cutting a target means RBC still likes the stock — but less than before. For Nuvation and Legend, the bank likely sees higher risk or slower progress in their pipelines compared to peers. The cuts suggest caution without a full retreat.
BioCryst Rally Backed by Strong Commercial Momentum
RBC's $14 target on BioCryst stands out because the bank paired it with a clear endorsement of the company's current rally, according to TipRanks. The bank pointed to strong biotech sector momentum as a key driver behind the upgraded target.
BioCryst makes treatments for rare diseases, including its drug ORLADEYO for hereditary angioedema. A rising price target from a major bank like RBC can attract new investors and push a stock higher in the short term. The Outperform rating adds further weight to that signal.
RBC's Mixed-Book Approach Reflects Uneven Biotech Landscape
The batch of notes shows RBC is not making one big bet on biotech as a whole. Instead, the bank is picking winners and losers stock by stock. Three names get higher targets. Two get lower ones. One, Exelixis, gets a raised target but only a Sector Perform rating — a more cautious call than Outperform.
RBC also revised targets for Cytokinetics, Cormedix, Axsome Therapeutics, and Ultragenyx Pharmaceutical in the same sweep. Cytokinetics and Cormedix saw their targets cut, while Axsome and Ultragenyx got increases, Benzinga reported. The pattern shows RBC is weighing each company's specific risks rather than following one broad sector view.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
22
Articles
1
Reach
23
A
AnonymousAuthor
